RE: 🔔 IMM mark 2 🔔 - Pharma & AI with 15B Nasdaq med-AI partner15 Sep 2025 09:31
Taken from ADVFN - Tell me this doesn't do 400%+ today?
Renalytix (LSE: RENX | OTCQB: RNLXY) – Bullish Breakthrough?
Date: 15 September 2025
Markets: London & New York
Portfolio Area: Pharmaceutical and Artificial Intelligence aka Medical AI
RNS Overview
Renalytix has just dropped a game-changing announcement that could set the stage for a bullish upside in their share price. Here's a breakdown of the RNS:
Major US Expansion & Collaboration with $15B Tempus AI
•Renalytix has signed a collaboration agreement with Tempus (NASDAQ: TEM), a powerhouse in AI-enabled diagnostics with a $15B valuation.
•This will bring kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for chronic kidney disease (CKD), into the hands of millions of eligible patients in the US.
•Impact: Nearly 15 million US patients with type 2 diabetes and CKD stages 1-3b can now access Renalytix’s precision medicine test. This is massive market penetration potential.
US Listing + Liquidity Boost
•As a US-listed stock (OTCQB: RNLXY), Renalytix now has direct access to US institutional and retail capital, which historically fuels hyper growth and rapid share price moves.
Collaboration is Strategic & High-Value
•KidneyintelX.dkd will be the first CKD test in Tempus’ portfolio, giving it a first-mover advantage in chronic kidney disease diagnostics.
•Leveraging Tempus’ broad clinical reach, Renalytix is positioned to scale quickly and efficiently, driving adoption and revenues.
Multi-Rise Potential – Similar to IMM
•Think IMM-style trajectory: small-cap biotech that transitions into multi-bagger territory post-FDA approval + strategic US partnerships.
•With this deal, Renalytix is poised for multi-stage upside, potentially mimicking the explosive growth curves seen in other precision medicine innovators.
Share Price Context – Potential
Year High (GBP pence)
2021 1100p
2022 540p
2023 140p
2024 40p
2025 12.99p
Insight: The stock is trading at multi-year lows (~$0.18 USD), even though its pipeline, FDA approval, and strategic US partnership point to massive upside potential.
Why This Could Trigger a Bull Run:
•FDA-approved & reimbursed test – ensures credibility and uptake.
•US network expansion – rapid scaling potential.
•Tempus collaboration – access to $15B AI-powered healthcare platform.
•Data-driven growth – multi-modal data collection could unlock new therapeutic/diagnostic innovations, driving long-term value.
Bottom line: Renalytix in my opinion is now positioned for a multi-rise scenario, US adoption surge, and investor attention. If the stock catches even a fraction of its full market potential, it could deliver well over IMM-style returns from these historical lows.
Sign In
Follow the stocks
